VIC-1911
As of the edition of 20 October 2026, VIC-1911 is a drug known only by a code name: stopped in 2023; acts on AURKA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Code name only
- Registered trials
- 3, 1 stopped early
- Disease areas
- Lungs and airways; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of VIC-1911.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AURKA | Aurora kinase A | O14965 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 1 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiesi Yingda Pharmaceutical Technology | Lead sponsor of trials | 2022 to now |
| Vitrac Therapeutics | Lead sponsor of trials | 2022 to now |